Background
Virological failure (VF) has been observed in people with HIV (PWH) receiving second-generation integrase (IN) strand transfer inhibitors (INSTIs) without IN resistance mutations. To elucidate alternative INSTI resistance mechanisms, we previously passaged HIV-1 in a T-cell line for ~1 year with escalating concentrations of the INSTI dolutegravir (DTG). HIV-1 developed resistance to DTG by sequentially acquiring mutations in Env, nucleocapsid (NC), and, in some cases, IN. Importantly, Env mutations not only conferred INSTI resistance but also compensated for infectivity defects caused by IN mutations. This study investigates the role of Env mutations in the acquisition of INSTI resistance mutations in IN and NC.
Methods
HIV-1NL4-3 was serially passaged (~2 years) in primary PBMCs in the presence of DTG or the first-generation INSTI, raltegravir (RAL). We evaluated the impact of selected mutations on replication kinetics and viral infection via cell-free or cell-cell transmission. In PBMCs, we cultured wild-type (WT) HIV-1NL4-3 or the DTG-selected HIVNL4-3 Env mutant (12 replicates each) with 2 nM DTG for 20 weeks. Viral DNA was quantified longitudinally, and GagPol regions were sequenced to monitor emerging mutations.
Results
In the presence of DTG, HIV-1 sequentially acquired mutations in Env, NC, and occasionally IN in PBMC. In contrast, HIV-1 exposed to RAL primarily developed canonical IN resistance mutations (e.g., IN-N155H). DTG-selected viruses exhibited heavily mutated Env (clone WD-3). WD-3 with only Env mutations conferred 5-fold resistance to DTG in PBMC by enhancing viral replication capacity. Importantly, viral DNA copies in WT-infected cells declined over time in the presence of DTG, whereas WD-3 DNA copies were stably maintained for 20 weeks, indicating that Env mutants sustained low-level virus replication in the presence of INSTIs. Sequence analysis revealed that many WD-3 cultures eventually accumulated additional IN and/or NC resistance mutations.
Conclusions
Our findings highlight that HIV-1 can exploit non-canonical resistance pathways to evade second-generation INSTIs. Env mutations function as a gateway for the stepwise acquisition of higher-level INSTI resistance through subsequent IN and/or NC mutations in cell culture. Ongoing studies will determine the clinical relevance of Env mutations in PWH who experience VF on INSTI-based regimens.